CSPG4 and myeloid sarcoma: Exogenous addition of activators, such as laminin, bFGF, and down-regulated NG2/CSPG4, may reverse deficient migration of MS-iPSCs-derived OPCs, suggesting that early OPCs migration capacity may be a potential target for restoring remyelination and neurological function (36).